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Abstract: Owing to their abilities to identify diseased conditions, 
to modulate biological process, and to control cellular activities, 
magnetic nanoparticles have become one of the most popular 
nanomaterials exploited in the biomedical field. Targeted drug 
delivery, controlled drug release, hyperthermia treatments, 
imaging, and stimulation of several biological entities are just 
some of the several tasks that can be accomplished by taking 
advantage of magnetic nanoparticles in tandem with magnetic 
fields. The huge interest towards this class of nanomaterials 
rises from the possibility to physically drive their spatiotemporal 
localization inside the body, and to deliver an externally applied 
stimulation at a target site. They in fact behave as actual 
nanotransducers, converting energy stemming from the external 
magnetic field into heat and mechanical forces, which act as 
signals for therapeutic processes as hyperthermia and controlled 
drug release. Magnetic nanoparticles result into a non-invasive 
tool that enables a remote activation of biological processes, 
besides behaving as formidable tracers for different imaging 
modalities, thus allowing to simultaneously carry out diagnosis 
and therapy. In view of all this, owing to their multifunctional and 
multitasking nature, magnetic nanoparticles are already one of 
the most important nanotechnological protagonists in medicine 
and biology, enabling an actual theranostic approach in many 
pathological conditions. In this Concept, we first provide a brief 
introduction on some physical properties of magnetic materials 
and on important features that determine the physical properties 
of magnetic nanoparticles; thereafter, we will consider some 
major biomedical applications: hyperthermia, drug delivery / 
release, and nanoparticle-mediated control of biological 
processes, even at subcellular level. 
Introduction 
Magnetic nanoparticles represent an important class of inorganic 
materials with attractive properties for biomedical applications. 
Iron oxide nanoparticles have been for example exploited as 
contrast agents since many decades in magnetic resonance 
imaging, and several examples of products approved by 
regulatory bodies can be found in the clinical practice.[1] 
However, in the latest years, their intriguing physical properties 
have been explored for many other applications in biology and 
medicine, and in this Concept report we will focus on those 
examples that, in our opinion, make magnetic nanoparticles 
actual smart and active nanotranducers. 
First of all, their physical features allow for a remote 
manipulation with external magnetic field gradients, thus 
enabling their positioning / targeting in desired sites. When 
envisioning drug delivery applications, this implies the possibility 
to physically transport a therapeutic molecule linked to the 
nanoparticle to the intended area, owing to a “wireless” guidance 
of the nanovectors following a system administration.[2] This 
strategy opens new perspectives in particular in the oncological 
field, offering the double advantage of reducing the aspecific 
systemic distribution of the compounds (in the most of the cases 
toxic also toward healthy tissues), and to instead increase their 
action at the target site, thus obtaining a more effective 
therapeutic treatment maintaining lower and safer drug doses.[2] 
Magnetic nanoparticles act moreover as transducers, able to 
convert a time-varying magnetic field into thermal and 
mechanical energy, suitable for inducing hyperthermia, drug 
release, and even for fostering specific cellular responses.[3] 
Magnetic nanoparticles suitable for biomedical applications can 
be essentially classified as ferromagnetic or superparamagnetic. 
[4] Ferromagnetic nanoparticles are generally multi-domain 
particles with size > 10 nm, own a large spontaneous 
magnetization, and M-H curves present a consistent hysteresis 
loop; if properly functionalized to avoid agglomeration, they can 
be very useful for hyperthermia applications.[5] 
Among the broad spectrum of magnetic nanomaterials 
investigated for biomedical purposes, those that exhibit 
superparamagnetic behavior at room temperature are however 
the most useful because of several favorable characteristics. 
Superparamagnetic nanoparticles own a magnetic moment that 
can be orientated upon the application of a remote magnetic 
field; following alignment of magnetic moments, resulting 
magnetization is different from zero and it increases 
proportionally to the applied field, but it is not preserved when 
magnetic field is removed.[6] In fact, in the case of mono-domain 
particles with size around 10 nm (like indeed the 
superparamagnetic ones), thermal fluctuations avoid 
establishment of a stable magnetization, and both the remanent 
magnetization (i.e., the value of the remaining magnetization 
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when the applied magnetic field returns to zero) and the 
coercitivity (i.e., the magnitude of the field that must be applied 
to cancel the remanent magnetization) are zero after removing 
the magnetic field, indicating that the material is no longer 
magnetized.[6] 
Owing to these peculiar features, superparamagnetic 
nanoparticles play an important role in biomedical applications, 
since a high magnetization value allows for a magnetic control in 
biological fluids, yet, however, the lack of a permanent 
magnetization avoids problems related to aggregation once the 
magnetic field is removed.[7] 
Besides a high magnetization value, necessary for an effective 
remote manipulation, biocompatibility and colloidal stability are 
crucial aspects especially for in vivo applications. At this aim, 
several synthesis strategies have been elaborated in the recent 
years to achieve appropriate shape, size distribution, 
dispersibility, and magnetic behaviors.[8] Iron oxides, in particular 
magnetite (Fe3O4) and maghemite (γ-Fe2O3), are the most 
common used materials for the synthesis of magnetic 
nanoparticles[9]. Superparamagnetic iron oxide nanoparticles 
(SPIONs) are non-toxic, biodegradable, biocompatible, and the 
iron ions resulting from their degradation are efficiently regulated 
via the metabolic pathways of Fe and by the innate clearance 
mechanism of the body.[9][10] 
Since bare SPIONs can be chemically very reactive, in particular 
under the action of oxidizing agents that can provoke loss of 
dispersibility and alteration of the magnetic properties, their use 
usually requires biocompatible coatings, able to preserve them 
from the action of the surrounding environment.[8] The coating of 
magnetic nanoparticles plays an extremely important role, 
fundamental for their successful exploitation: it avoids 
flocculation, preserves magnetic properties, and can be even 
used as targeting agent toward specific biological structures. 
Polymers, surfactants, biomolecules, or inorganic layer such as 
silica, metal, metal sulfide, and metal oxide have been 
extensively proposed to provide appropriate coating or grafting 
to magnetic nanoparticles.[1] 
Size, shape, and surface features of nanoparticles moreover 
determine their biological distribution:[11] in particular, 
nanovectors should be small enough to bypass body 
surveillance systems, thus avoiding removal from blood 
circulation,[12] overcoming several anatomic barriers,[13] and, 
finally, crossing the fenestrations of the blood capillaries in order 
to penetrate tissues.[14] Control of the surface characteristics is 
instead decisive to obtain a non-toxic and stable colloidal 
suspension in physiological solutions, and to ensure a well 
sustained cellular uptake.[11][15] At this regard, several active 
targeting strategies have been proposed to facilitate the 
accumulation of magnetic complexes at a intended site with high 
specificity, that exploit surface functionalization with specific 
moieties able to selectively bind the intended cells and tissues. 
[15] 
Magnetic Hyperthermia 
Due to their capability to convert energy form alternating 
magnetic fields into heat, magnetic nanoparticles can be used to 
locally and precisely increase temperature (up to 42-45°C and 
even above) in hyperthermia treatments, particularly useful in 
the oncology field.[16] Literally, “hyperthermia” means increment 
of temperature, and it is an old technique that exploits the 
deleterious effects of the heat on the cellular structures, such as 
membranes, cytoskeleton and nuclei.[17] Because of the chaotic 
and disordered organization of the tumor blood vessels, heat is 
more difficultly dissipated in diseased sites with respect to 
healthy tissues, thus provoking a more consistent damage both 
in terms of cell apoptosis (programmed and active energy-
dependent cell death following negative cues) and necrosis 
(passive cell death following fatal injuries).[18] Furthermore, 
hyperthermia can be mostly useful also as supporting treatment 
in traditional oncological approaches like chemotherapy and 
radiotherapy, since a mild, even sub-lethal, increment of 
temperature makes cells more sensitive to these therapeutic 
strategies[19][20]. 
The approach consisting in the induction of a temperature 
increment through the use of magnetic nanoparticles is referred 
to as magnetic fluid hyperthermia (MFH);[16] with respect to other 
methods, MFH offers the advantage of a direct contact between 
heat source and tumor cells, thus ensuring a greater selectivity 
and efficacy.[21] MFH in fact relies on the local heating of the 
tumor tissue by using magnetic nanoparticles, selectively 
delivered to the tumor area through a local or systemic 
administration (Figure 1). Upon alternating, non-invasive, 
electromagnetic stimulation, heat production is thereafter 
associated to the rotation of the magnetic moment within each 
particle (Néel relaxation) and to the rotation of particles 
themselves within a viscos fluid (Brown relaxation)[22]. 
After the first experimental studies about the use of magnetic 
nanoparticles for hyperthermia performed in 1957 by Gilchrist et 
al.,[23] twenty years later many works demonstrated hyperthermia 
effects obtained on several animal models with different types of 
magnetic nanoparticles,[24][25][26] and with several methods of 
encapsulation and delivery of the nanoparticles within the 
tumor.[27][28] Most importantly, the feasibility and the efficacy of 
this approach were also confirmed by clinical trials,[29][30][31][32] 
indeed receiving regulatory approval as a new clinical therapy in 
2010.[33] 
Currently, major efforts are addressed to optimize nanoparticle 
heating efficiency in order to obtain a therapeutic effect with an 
as lowest as possible amount of nanoparticles. Such approach 
would allow to achieve appropriate temperatures also in those 
areas where the magnetic material accumulation is poor due to 
the tumor anatomy and physiology.[21] 
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Figure 1. Schematic representation of magnetic fluid hyperthermia in cancer 
therapy. Reprinted with permission from [16]. Copyright (2005) Elsevier. 
The amount of heat generated by colloidal suspension of 
magnetic nanoparticle is evaluated in terms of specific 
absorption rate (SAR), and such parameter depends on several 
properties of the nanovectors, including composition of magnetic 
material,[34] size,[35] shape,[36] magnetic anisotropy, and 
saturation magnetization,[37] and on the amplitude and frequency 
of the applied magnetic field.[36] Particles with high magnetization 
values, with an optimal anisotropy constant and highly 
monodispersed ensure high SAR values for an effective 
hyperthermia treatment.[34] Concerning magnetic field 
parameters, SAR is an increasing function of amplitude and 
frequency of the magnetic field. However, it is mandatory to 
work with frequencies capable to harmlessly pass through the 
body, and to generate heat just in the sites containing magnetic 
nanoparticles, without affecting healthy tissues:[38] the high 
penetrability of magnetic fields to human body without significant 
attenuation (at a frequency range of about 50-500 kHz) is the 
key point that makes hyperthermia a successful non-invasive 
therapeutic approach.[36] 
Administration method of magnetic nanoparticles is also 
fundamental in order to achieve an efficient heat treatment. 
Magnetic fluid should be in fact accumulated and restricted to 
the tumor site in order to both limit adverse side effects and to 
allow repetition of several treatment cycles. Generally, magnetic 
nanoparticles are placed inside the tumor through direct 
injection,[39] or alternatively they reach the diseased area thanks 
to a targeting upon intravenous injection.[40] 
Magnetic Drug Delivery 
The idea of using magnetic nanoparticles for targeted drug 
delivery dates to 1970:[41] the rationale is the conjugation of a 
drug to a magnetically responsive carrier, in order to drive and 
concentrate its cytotoxic effect in a specific area by means of an 
external magnet, previously placed close to diseased tissue 
(Figure 2). The major advantage of a magnetic nanoparticle-
mediated targeting with respect to other drug delivery strategies 
relies on the possibility to monitor the spatiotemporal movement 
of the carrier through magnetic resonance imaging, by exploiting 
contrast properties of the magnetic nanoparticles.[2] The 
multifunctional nature of the nanovector allows the obtainment of 
a real “theranostic” platform, owing to the combination into a 
single nanodevice of a therapeutic treatment, by increasing the 
delivery of a cytotoxic compound at the target site, and of 
diagnosis, by monitoring the response to the therapy through 
non-invasive imaging techniques.[42] Over the years such 
approach has been thus used for the targeted delivery of 
chemotherapeutic drugs,[43] radionuclides,[44] and genes,[45] by 
exploiting several strategies of synthesis of magnetic 
nanoparticles and by designing magnetic drug delivery systems 
(MDDS) with specific biological, chemical and physical 
properties.[8] 
Therapeutic compounds can be directly linked to the surface of 
the magnetic nanoparticles or encapsulated into magnetic 
nanocarriers having a core-shell structure, where magnetic iron 
oxide nanoparticles are surrounded by polymers, metals, or 
lipids.[2][11][46] Generally, such approach is used in anticancer 
therapies, and first clinical trials were reported by Lübbe et al., 
that exploited epidoxorubicin-coated magnetic nanoparticles for 
the treatment of inoperable solid tumors.[47] Since then, many 
examples of magnetic drug delivery systems have been reported 
by using different animal models.[48][49] Very interesting, as an 
example, is the work of Kubo et al.,[50] where a permanent 
magnet was implanted at the tumor site in hamsters to increase 
accumulation of magnetic liposomes containing a cytotoxic 
compound. These encouraging results pushed Pulfer et al. to 
use a similar approach to target drugs to a rat glioma.[51] 
To date, no MDDS has been yet approved for clinical use, 
however some of them entered into clinical trials, with important 
promising outcomes.[47][52] Among the many difficulties that these 
new nanoplatforms experience in the clinical fields, the most 
important ones are related to the possibility of reaching the 
intended site, that often is represented by a depth tumor 
tissue.[53] Moreover, during their “travel” in the human body, 
magnetic nanoparticles experience interactions with vessel 
walls, anatomical barriers, and penetration through various 
tissue types, and their behavior under the action of a magnetic 
field is influenced by several physiological variables (first of all 
the blood flow) so that size, shape, and geometry of the particles 
as well as strength of the magnetic field are just some of the 
features we have to consider when designing a MDDS.[53] 
Once that the nanoparticles are concentrated at the target site 
and are internalized by tumor cells, the following step is 
represented by the release of the encapsulated drug from the 
carrier, with an appropriate rate compatible with the therapeutic 
goals. Dealing with MDDSs, the application of an appropriate 
external magnetic stimulus has been demonstrated to be a 
suitable trigger of drug release.[54][55] Such approach exploits the 
combination of magnetic nanoparticles with stimuli-responsive 
materials (as an example polymers or lipids), able to change 
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their conformation and structure in response to an external cue, 
like an increment of temperature or mechanical stresses.[56] 
Magnetic nanoparticles integrated in thermally- or mechanically-
responsive structures result able to induce conformational 
changes following heat or vibrations generated by exposure to 
magnetic fields,[57] thus inducing a release of the drug in a well-
controlled and sustained manner. 
 
Figure 2. Schematic representation of magnetic drug targeting. Reprinted with 
permission from [43]. Copyright (2011) Elsevier. 
Magnetic nanoparticles for cell activities 
control 
Another potential intriguing application of magnetic nanoparticles 
is represented by the possibility to modulate cell functions and 
responses by activating signal transduction mechanisms through 
stimulation of cells or sub-cellular entities. Cellular receptors can 
be in fact activated by simultaneous binding of multi-valent 
signaling molecules; such multi-valent signaling molecules can 
be mimicked by appropriately targeted magnetic nanoparticles 
that, in the presence of external magnetic fields, act as 
nanotransducers by fostering cell behaviors and, at the same 
time, by preventing non-specific activation.[3] 
Cell functions are regulated by macromolecules able to perceive 
and to respond to stimuli and changes from the surrounding 
environment. Generally, a signal molecule recognizes and binds 
a membrane or intracellular receptor, which in turn activates a 
particular metabolic pathway. The final outcome is the fostering 
of a well-defined behavior, like variation of the cytoskeleton 
organization, gene transcription activation, changes of 
membrane permeability, etc.[58]. Magnetic nanoparticles can be 
used as actual “switchers” for the manipulation of cell functions 
and of molecular pathways: following an appropriate 
functionalization with specific ligands, the nanovectors are able 
to bind biological receptors in cells, owing to their small size.[58] 
Thereafter, the application of a remote magnetic field produces 
mechanical or thermal stimulation able to alter the receptor 
functionalities[56] (Figure 3). 
 
Figure 3. Schematic representation of magnetic nanoparticle-mediated 
activation of cell signaling. Reprinted with permission from [58]. Copyright 
(2011) American Chemical Society. 
In this regard, magnetically generated mechanical stimuli have 
been for example exploited for the activation of integrin 
receptors bound to magnetic particles.[59] Authors demonstrated 
that, if the magnetic field is strong enough to generate a twist of 
the nanoparticles, or to pull them towards the magnetic field 
source, receptors perceive the mechanical cue and 
subsequently activate a cellular signaling pathway.[59] El Haj et 
al. focused instead their work on the use of magnetic 
nanoparticles for a selective and precise activation of 
mechanosensitive ion channels, without interfering with the 
normal functions of other channels on the cell membrane.[60] 
Mannix and colleagues demonstrated that a similar strategy can 
be used to modulate the spatial organization of membrane 
receptors.[61] Authors exploited a magnetic needle to concentrate 
magnetic forces on a small area, in order to induce an 
aggregation of nanoparticles previously coated with ligands for 
binding specific transmembrane receptors. Aggregation of the 
magnetic nanoparticles induced the clustering of the receptors, 
thus activating a cellular response.[61] Magnetically-driven 
clustering of receptors represents a new and impressive 
opportunity to regulate a plenty of cellular and biological 
processes that are activated by the clustering of membrane 
receptors. As an example, some groups exploited this strategy 
for the control of the metabolic pathways involved in 
angiogenesis (i.e., the development of new blood vessels during 
the tumor formation),[62] and for fostering programmed cell 
death.[63] 
As a final remark, magnetic nanoparticles constitute a valid tool 
for cell signaling transduction control through selective heat 
generation at the level of specific heat-sensitive cellular 
component, such as some classes of ion channels. Huang et al. 
succeeded in triggering action potentials in cultured neurons 
previously treated with superparamagnetic ferrite nanoparticles 
able to target temperature-sensitive ion channel TRPV1.[64] 
Application of alternating magnetic fields induced the heating of 
the nanoparticles, provoking the opening of the TRPV1 channels 
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with a consequent influx of calcium ions, thus inducing the 
generation of action potentials.[64] 
Conclusions 
Magnetic nanoparticles are an interesting class of nanomaterials 
with extraordinary potentials in biological and medical fields. 
They represent one of the first and few examples of 
nanotechnological products already approved in the clinical 
practice, as contrast agents in magnetic resonance imaging.[65] 
However, just considering magnetic nanovectors as a diagnostic 
tool is extremely limiting: as summarized in this Concept paper, 
magnetic nanoparticles are actual theranostic, multifunctional, 
and multistage nanoplatforms, that offer unprecedented aid in 
drug delivery, drug targeting and thermal therapy, besides more 
traditional imaging applications. Although the obtained findings 
are overall promising, many questions are however still open, 
including long-term fate, bioaccumulation, and biodegradability 
issues, that should be adequately addressed before a wide 
spreading of magnetic nanovectors in the future clinical practice, 
and in the development of innovative subcellular 
nanotransducers. 
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